New Insights into Tubulin Binders
作者： Carles Escriu , James D. Brenton
DOI: 10.1007/978-1-4419-7216-3_13
关键词:
摘要: Tubulin-binding agents have traditionally been divided into compounds that promote tubulin polymerization (microtubule-stabilizing exemplified by the prototypic taxane paclitaxel and docetaxel) those depolymerization, including vinca alkaloids (vincristine, vinblastine vinorelbine). Only taxanes significant activity in treatment of epithelial ovarian cancer either as single-agent therapy or combination with platinum (Muggia et al. (2000), Covens (2002), International Collaborative Ovarian Neoplasm Group Parmar (2003), Kyrgiou (2006)). However, despite their utility, important clinical limitations, particularly related to drug resistance adverse effects. This review will focus on current understanding how biology microtubule control cell cycle may explain inform development new therapeutics strategies.
springer.com
springerlink.com参考文章(117)
Noriyuki Katsumata, Makoto Yasuda, Fumiaki Takahashi, Seiji Isonishi, Toshiko Jobo, Daisuke Aoki, Hiroshi Tsuda, Toru Sugiyama, Shoji Kodama, Eizo Kimura, Kazunori Ochiai, Kiichiro Noda, Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial The Lancet. ,vol. 374, pp. 1331- 1338 ,(2009) , 10.1016/S0140-6736(09)61157-0
Pascal Sève, Charles Dumontet, Is class III β-tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncology. ,vol. 9, pp. 168- 175 ,(2008) , 10.1016/S1470-2045(08)70029-9
Richard J. Kowalski, Paraskevi Giannakakou, Ernest Hamel, Activities of the Microtubule-stabilizing Agents Epothilones A and B with Purified Tubulin and in Cells Resistant to Paclitaxel (Taxol®) Journal of Biological Chemistry. ,vol. 272, pp. 2534- 2541 ,(1997) , 10.1074/JBC.272.4.2534
Maria Kyrgiou, Georgia Salanti, Nicholas Pavlidis, Evangelos Paraskevaidis, John P. A. Ioannidis, Survival Benefits With Diverse Chemotherapy Regimens for Ovarian Cancer: Meta-analysis of Multiple Treatments Journal of the National Cancer Institute. ,vol. 98, pp. 1655- 1663 ,(2006) , 10.1093/JNCI/DJJ443
Ravat Panvichian, Kim Orth, Mark L Day, Kathleen C Day, Mary Josephine Pilat, Kenneth J Pienta, None, Paclitaxel-associated Multimininucleation Is Permitted by the Inhibition of Caspase Activation: A Potential Early Step in Drug Resistance Cancer Research. ,vol. 58, pp. 4667- 4672 ,(1998)
Tito Fojo, Peter J. Oefner, George E. Duran, Peidong Shen, Branimir I. Sikic, Yan Wang, Kristine Yu, Raphael Sung, Sanja Šale, Jong-Hyeok Kim, Conservation of the Class I -Tubulin Gene in Human Populations and Lack of Mutations in Lung Cancers and Paclitaxel-resistant Ovarian Cancers 1 Molecular Cancer Therapeutics. ,vol. 1, pp. 215- 225 ,(2002)
Wim W. ten Bokkel Huinink, Jozef Sufliarsky, Willem M. Smit, Stanislav Spanik, Maria Wagnerova, Hal W. Hirte, Stan Kaye, Anandhi R. Johri, Amit M. Oza, Safety and Efficacy of Patupilone in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer: A Phase I, Open-Label, Dose-Escalation Study Journal of Clinical Oncology. ,vol. 27, pp. 3097- 3103 ,(2009) , 10.1200/JCO.2008.20.4826
Tiffani A. Cook, Takayuki Nagasaki, Gregg G. Gundersen, Rho Guanosine Triphosphatase Mediates the Selective Stabilization of Microtubules Induced by Lysophosphatidic Acid Journal of Cell Biology. ,vol. 141, pp. 175- 185 ,(1998) , 10.1083/JCB.141.1.175
Patrick G. Morris, Monica N. Fornier, Microtubule active agents: beyond the taxane frontier. Clinical Cancer Research. ,vol. 14, pp. 7167- 7172 ,(2008) , 10.1158/1078-0432.CCR-08-0169
Elizabeth Alli, Jin-Ming Yang, James M. Ford, William N. Hait, Reversal of Stathmin-Mediated Resistance to Paclitaxel and Vinblastine in Human Breast Carcinoma Cells Molecular Pharmacology. ,vol. 71, pp. 1233- 1240 ,(2007) , 10.1124/MOL.106.029702